Gilead Sciences Posts Q1 EPS Beat but Revenue Falls Short Amid Mixed Product Performance

HIV and liver disease drug sales bolstered earnings, while oncology, COVID antiviral, and cell therapy segments underperformed, prompting reaffirmation of full-year guidance.